JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Published on 22 Nov 2024 on Zacks · via Yahoo Finance

Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific...

Read the rest of the article

Start tracking your investments with Statfolio

We recently published a list of 8 Most Undervalued Pot Stocks to Buy According to Analysts. In th...

Insider Monkey · via Yahoo Finance 28 Nov 2024

On Tuesday, Axsome Therapeutics Inc (NASDAQ:AXSM) said AXS-12 statistically significantly reduced...

Benzinga · via Yahoo Finance 27 Nov 2024

Shares of CDXC have been soaring, and the company still appears to be a decent choice, but what...

Zacks · via Yahoo Finance 23 Nov 2024

Dosing is expected to begin in the first quarter of 2025. JAZZ Wins Drug Approval Jazz...

Zacks · via Yahoo Finance 22 Nov 2024

Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific...

Zacks · via Yahoo Finance 22 Nov 2024

The drug zanidatamab-hrii, sold under the brand name Ziihera, is approved for use in previously...

Reuters 21 Nov 2024

Silver Ring Value Partners, an investment management company, released its third-quarter 2024...

Insider Monkey · via Yahoo Finance 19 Nov 2024

On Monday, Baird made a positive adjustment to Jazz Pharmaceuticals ' (NASDAQ:JAZZ) financial...

Investing.com 19 Nov 2024

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we a...

Insider Monkey · via Yahoo Finance 18 Nov 2024

Jazz Pharmaceuticals PLC (JAZZ) reports robust financial performance with significant growth in k...

GuruFocus.com · via Yahoo Finance 6 Nov 2024